Structure-based drug design of small molecule SIRT1 modulators to treat cancer and metabolic disorders

Journal of Molecular Graphics and Modelling

Volumn 52, Issue , 2014, Pages 46-56

  Pulla, Venkat Koushik ^a   Alvala, Mallika ^a   Sriram, Dinavahi Saketh ^a,b   Viswanadha, Srikant ^b   Sriram, Dharmarajan ^a   Yogeeswari, Perumal ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b Drug Metabolism and Pharmacokinetics Division   (India)

Author keywords

Adipogenesis differentiation; Cell cycle analysis; Docking; High through virtual screening; SIRT1 activators; SIRT1 inhibitors

Indexed keywords

AMINO ACIDS; DISEASES; DOCKING; DRUG DELIVERY; METABOLISM; MOLECULES; NUTRITION;

ADIPOGENESIS; CELL CYCLE; HISTONE DEACETYLASES; METABOLIC DISORDERS; SIRT1 ACTIVATORS; SMALL MOLECULE INHIBITOR; STRUCTURE-BASED DRUG DESIGN; VIRTUAL SCREENING;

STRUCTURAL DESIGN;

ANTINEOPLASTIC AGENT; ENZYME ACTIVATOR; ENZYME INHIBITOR; GEMCITABINE; RESVERATROL; SIRTINOL; SIRTUIN 1; SIRTUIN 1 ACTIVATOR; SIRTUIN 1 INHIBITOR; SURAMIN; UNCLASSIFIED DRUG; MOLECULAR LIBRARY;

ADIPOGENESIS; ALLOSTERISM; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; METABOLIC DISORDER; MOLECULAR DOCKING; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TISSUE DIFFERENTIATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ASSAY; FLUORESCENCE; HEK293 CELL LINE; IC50; METABOLIC DISEASES; MOLECULAR LIBRARY; MOUSE; NEOPLASMS; PHARMACOKINETICS; PHARMACOLOGY; THERAPEUTIC USE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; DRUG DESIGN; ENZYME ASSAYS; FLUORESCENCE; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; METABOLIC DISEASES; MICE; MODELS, MOLECULAR; NEOPLASMS; SIRTUIN 1; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903975952     PISSN: 10933263     EISSN: 18734243     Source Type: Journal    
DOI: 10.1016/j.jmgm.2014.06.005     Document Type: Article

References (38)

1. M.C. Haigis, and L.P. Guarente Mammalian sirtuins: emerging roles in physiology, aging, and calorie restriction Genes Dev. 20 21 2006 2913 2921
2. +-dependent tubulin deacetylase Mol. Cell 11 2 2003 437 444
3. G. Donmez, and L. Guarente Aging and disease: connections to sirtuins Aging Cell 9 2 2010 285 290
4. K.M. Ramsey, K.F. Mills, A. Satoh, and S.I. Imai Ageing Cell 7 2008 78 88
5. M.C. Haigis, and D.A. Sinclair Mammalian sirtuins: biological insights and disease relevance Annu. Rev. Pathol. 5 2010 253
6. + dependent histone deacetylases (sirtuins) Curr. Pharm. Des. 14 2008 562 573
7. R.C. Neugebauer, U. Uchiechowska, R. Meier, H. Hruby, V. Valkov, E. Verdin, W. Sippl, and M. Jung Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode J. Med. Chem. 51 5 2008 1203 1213
8. A.D. Napper, J. Hixon, T. McDonagh, K. Keavey, J.-F. Pons, J. Barker, W.T. Yau, P. Amouzegh, A. Flegg, and E. Hamelin Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1 J. Med. Chem. 48 25 2005 8045 8054
9. A. Bedalov, T. Gatbonton, W.P. Irvine, D.E. Gottschling, and J.A. Simon Identification of a small molecule inhibitor of Sir2p Proc. Natl. Acad. Sci. U. S. A. 98 26 2001 15113 15118
10. J. Posakony, M. Hirao, S. Stevens, J.A. Simon, and A. Bedalov Inhibitors of Sir2: evaluation of splitomicin analogues J. Med. Chem. 47 10 2004 2635 2644
11. A. Mai, S. Massa, S. Lavu, R. Pezzi, S. Simeoni, R. Ragno, F.R. Mariotti, F. Chiani, G. Camilloni, and D.A. Sinclair Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors J. Med. Chem. 48 24 2005 7789 7795
12. F. Medda, R.J. Russell, M. Higgins, A.R. McCarthy, J. Campbell, A.M. Slawin, D.P. Lane, S. Lain, and N.J. Westwood Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity J. Med. Chem. 52 9 2009 2673 2682
13. T. Suzuki, K. Imai, H. Nakagawa, and N. Miyata 2-Anilinobenzamides as SIRT inhibitors ChemMedChem 1 10 2006 1059 1062
14. C. Gey, S. Kyrylenko, L. Hennig, L.H.D. Nguyen, A. Büttner, H.D. Pham, and A. Giannis Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2 Angew. Chem. Int. Ed. 46 27 2007 5219 5222
15. P.H. Kiviranta, J. Leppänen, V.M. Rinne, T. Suuronen, O. Kyrylenko, S. Kyrylenko, E. Kuusisto, A.J. Tervo, T. Järvinen, and A. Salminen N-(3-(4-hydroxyphenyl)-propenoyl)-amino acid tryptamides as SIRT2 inhibitors Bioorg. Med. Chem. Lett. 17 9 2007 2448 2451
16. B.D. Sanders, B. Jackson, and R. Marmorstein Structural basis for sirtuin function: what we know and what we don't Biochim. Biophys. Acta 1804 8 2010 1604 1616
17. T. Huhtiniemi, C. Wittekindt, T. Laitinen, J. Leppänen, A. Salminen, A. Poso, and M. Lahtela-Kakkonen Comparative and pharmacophore model for deacetylase SIRT1 J. Comput. Aided Mol. Des. 20 9 2006 589 599
18. I. Autiero, S. Costantini, and G. Colonna Human sirt-1: molecular modeling and structure-function relationships of an unordered protein PLoS ONE 4 10 2009 e7350
19. +) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition J. Med. Chem. 56 3 2013 963 969
20. M.S. Finnin, J.R. Donigian, and N.P. Pavletich Structure of the histone deacetylase SIRT2 Nat. Struct. Biol. 8 7 2001 621 625 10.1038/89668
21. M.T. Borra, B.C. Smith, and J.M. Denu Mechanism of human SIRT1 activation by resveratrol J. Biol. Chem. 280 17 2005 17187 17195
22. J.L. Avalos, J.D. Boeke, and C. Wolberger Structural basis for the mechanism and regulation of Sir2 enzymes Mol. Cell 13 5 2004 639 648
23. K. Zhao, X. Chai, and R. Marmorstein Structure of the yeast Hst2 protein deacetylase in ternary complex with 2′-O-acetyl ADP ribose and histone peptide Structure 11 11 2003 1403 1411
24. A. Sharma, V. Gautam, S. Costantini, A. Paladino, and G. Colonna Interactomic and pharmacological insights on human Sirt-1 Front. Pharmacol. 3 2012 40 43
25. J.C. Milne, P.D. Lambert, S. Schenk, D.P. Carney, J.J. Smith, D.J. Gagne, L. Jin, O. Boss, R.B. Perni, and C.B. Vu Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes Nature 450 7170 2007 712 716
26. M. Pacholec, J.E. Bleasdale, B. Chrunyk, D. Cunningham, D. Flynn, R.S. Garofalo, D. Griffith, M. Griffor, P. Loulakis, and B. Pabst SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1 J. Biol. Chem. 285 11 2010 8340 8351
27. M. Lakshminarasimhan, D. Rauh, M. Schutkowski, and C. Steegborn Sirt1 activation by resveratrol is substrate sequence-selective Aging (Albany, NY) 5 3 2013 151
28. B.P. Hubbard, A.P. Gomes, H. Dai, J. Li, A.W. Case, T. Considine, T.V. Riera, J.E. Lee, S. Yen, and D.W. Lamming Evidence for a common mechanism of SIRT1 regulation by allosteric activators Science 339 6124 2013 1216 1219
29. H. Dai, L. Kustigian, D. Carney, A. Case, T. Considine, B.P. Hubbard, R.B. Perni, T.V. Riera, B. Szczepankiewicz, and G.P. Vlasuk SIRT1 activation by small molecules kinetic and biophysical evidence for direct interaction of enzyme and activator J. Biol. Chem. 285 43 2010 32695 32703
30. V.K. Pulla, M.B. Battu, M. Alvala, D. Sriram, and P. Yogeeswari Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review Expert Opin. Ther. Targets 16 8 2012 819 832
31. LigPrep, Version 2.5 2011 Schrodinger, LLC New York, NY
32. Canvas, Version 1.4 2011 Schrodinger, LLC New York, NY
33. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, and J.K. Perry Glide - a new approach for rapid, accurate docking and scoring: 1. Method and assessment of docking accuracy J. Med. Chem. 47 7 2004 1739 1749
34. V.M. Nayagam, X. Wang, Y.C. Tan, A. Poulsen, K.C. Goh, T. Ng, H. Wang, H.Y. Song, B. Ni, and M. Entzeroth SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents J. Biomol. Screen. 11 8 2006 959 967
35. J.A. Plumb Cell sensitivity assays: the MTT assay Cancer Cell Culture 2004 Springer Totowa, NJ 165 169
36. M.-S. Kim, J.-K. Kim, D.-Y. Kwon, and R. Park Anti-adipogenic effects of Garcinia extract on the lipid droplet accumulation and the expression of transcription factor Biofactors 22 1 2004 193 196
37. Y. Zhang, Y. Cheng, X. Ren, T. Hori, K.J. Huber-Keener, L. Zhang, K.L. Yap, D. Liu, L. Shantz, and Z.-H. Qin Dysfunction of nucleus accumbens-1 activates cellular senescence and inhibits tumor cell proliferation and oncogenesis Cancer Res. 72 16 2012 4262 4275
38. J.-H. Chang, H.-C. Kim, K.-Y. Hwang, J.-W. Lee, S.P. Jackson, S.D. Bell, and Y. Cho Structural basis for the NAD-dependent deacetylase mechanism of Sir2 J. Biol. Chem. 277 37 2002 34489 34498